EHS
EHS

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma


  • Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Balakrishnan, M., George, R., Sharma, A. & Graham, D. Y. Changing trends in stomach cancer throughout the world. Curr. Gastroenterol. Rep. 19, 36 (2017).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Gastric Cancer, Version 2. (2022). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434.

  • Muro, K. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann. Oncol. 30, 19–33 (2019).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Wagner, A. D. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8, 004064 (2017).


    Google Scholar
     

  • Moreira, A. M. et al. The extracellular matrix: An accomplice in gastric cancer development and progression. Cells 9, 394 (2020).

    CAS 
    PubMed Central 
    Article 

    Google Scholar
     

  • Yang, Q. et al. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat. Rec. 293, 2012–2019 (2010).

    CAS 
    Article 

    Google Scholar
     

  • Shah, M. A. et al. Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study. Clin. Cancer Res. 24, 3829–3837 (2018).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 92, 827–839 (2003).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Bramhall, S. R. et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br. J. Cancer. 86, 1864–1870 (2002).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Baragaño Raneros, A., Suarez-Álvarez, B. & López-Larrea, C. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. Oncoimmunology. 3, e28497 (2014).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141, 52–67 (2010).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z. & Colombo, M. P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67, 11438–11446 (2007).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Liu, L., Ye, Y. & Zhu, X. MMP-9 secreted by tumor associated macrophages promoted gastric cancer metastasis through a PI3K/AKT/Snail pathway. Biomed. Pharmacother. 117, 109096 (2019).

    PubMed 
    Article 
    CAS 

    Google Scholar
     

  • Oliveira, M. J. et al. Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner. J. Biol. Chem. 281, 34888–34896 (2006).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Kitadai, Y. et al. Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochem. Biophys. Res. Commun. 311, 809–814 (2003).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311–1315 (1984).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Chen, J. et al. Prognostic value of matrix metalloproteinase-9 in gastric cancer: A meta-analysis. Hepatogastroenterology. 61, 518–524 (2014).

    PubMed 

    Google Scholar
     

  • Jia, X., Lu, M., Rui, C. & Xiao, Y. Consensus-expressed CXCL8 and MMP9 identified by meta-analyzed perineural invasion gene signature in gastric cancer microarray data. Front. Genet. 10, 851 (2019).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Yao, Z. et al. MMP-2 together with MMP-9 overexpression correlated with lymph node metastasis and poor prognosis in early gastric carcinoma. Tumour Biol. 39, 1010428317700411 (2017).

    PubMed 

    Google Scholar
     

  • Wroblewski, L. E., Pritchard, D. M., Carter, S. & Varro, A. Gastrin-stimulated gastric epithelial cell invasion: The role and mechanism of increased matrix metalloproteinase 9 expression. Biochem. J. 365, 873–879 (2002).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Chang, X. et al. NDRG1 controls gastric cancer migration and invasion through regulating MMP-9. Pathol. Oncol. Res. 22, 789–796 (2016).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Marshall, D. C. et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS ONE 10, e0127063 (2015).

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • Koizumi, W. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9, 215–221 (2008).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann. Oncol. 26, 141–148 (2015).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Lee, K. W. et al. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer 24, 156–167 (2021).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. (2010). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf.

  • Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247 (2009).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Yamaguchi, K. et al. Phase 1b study of andecaliximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma. J. Clin. Oncol. 37, 137–137 (2019).

    Article 

    Google Scholar
     

  • Yoshikawa, A. K. et al. Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: A phase 1b study. J. Immunother. Cancer. 10, e003518 (2022).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • JGC Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 24, 1–21 (2021).

    Article 

    Google Scholar
     

  • Boku, N. et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10, 1063–1069 (2009).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Shah, M. A. et al. Phase III study to evaluate efficacy and safety of andecaliximab with mFOLFOX6 as first-line treatment in patients with advanced gastric or GEJ adenocarcinoma (GAMMA-1). J. Clin. Oncol. 39, 990–1000 (2021).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Catenacci, D. V. T. et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J. Clin. Oncol. 39, 4010–4010 (2021).

    Article 

    Google Scholar
     

  • Ooki, A. & Yamaguchi, K. The dawn of precision medicine in diffuse-type gastric cancer. Ther. Adv. Med. Oncol. 14, 17588359221083048 (2022).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Zhao, R. et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. Cancer Lett. 287, 150–156 (2010).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Shao, L. et al. MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells. Biochem. Biophys. Res. Commun. 493, 1478–1484 (2017).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Heissig, B. et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109, 625–637 (2002).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Denney, H., Clench, M. R. & Woodroofe, M. N. Cleavage of chemokines CCL2 and CXCL10 by matrix metalloproteinases-2 and -9: Implications for chemotaxis. Biochem. Biophys. Res. Commun. 382, 341–347 (2009).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Shah, M. A. et al. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. J. Immunother. Cancer. 9, 1–10 (2021).


    Google Scholar
     

  • Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234–247 (2022).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Chen, S. Z. et al. Expression levels of matrix metalloproteinase-9 in human gastric carcinoma. Oncol. Lett. 9, 915–919 (2015).

    PubMed 
    Article 

    Google Scholar
     

  • Redondo-Muñoz, J. et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112, 169–178 (2008).

    PubMed 
    Article 
    CAS 

    Google Scholar
     

  • Takaishi, S. et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 27, 1006–1020 (2009).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19, 387–400 (2011).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Yosef, G., Hayun, H. & Papo, N. Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy. Biochem. J. 478, 1139–1157 (2021).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Alford, V. M. et al. Targeting the hemopexin-like domain of latent matrix metalloproteinase-9 (proMMP-9) with a small molecule inhibitor prevents the formation of focal adhesion junctions. ACS Chem. Biol. 12, 2788–2803 (2017).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     



  • Source link

    EHS
    Back to top button